Arius announces new findings in Trop-2 and CD59 CANCER antibody programs

CD59 antibody uses novel approach to "de-cloak" cancers

30-Oct-2007

ARIUS Research Inc. announced that new findings have been presented from its Trop-2 and CD59 antibody programs.

"Both our Trop-2 and CD59 antibody programs have demonstrated novel approaches in treating cancer. Our Trop-2 antibody is a novel target and has been linked to aggressive cancers in the scientific literature, while our CD59 program has demonstrated the ability to foil a cancer cell's ability to evade the immune system," said Dr. David Young, President and CEO. "These programs, in addition to our CD44 cancer stem cell program, were generated through our proprietary drug discovery technology, FunctionFIRST(TM), which is inherently designed to produce novel antibodies and identify unique cancer targets."

ARIUS' Trop-2 targeting antibody has demonstrated a significant anti-tumor effect in animal models of human pancreatic cancer, inhibiting tumor growth by up to 100 percent. Subsequent testing showed efficacy in animal models of breast, colon and prostate cancers. The antibody compared favorably with Taxotere in prostate cancer model and has also shown the ability to be highly potent at low-dose concentrations.

ARIUS has demonstrated that CD59 is commonly used to protect cancer cells from being destroyed. According to the company, ARIUS' CD59 targeting antibody provides a novel approach to "de-cloak" cancers. The CD59 targeting antibody activates complement activity against cancer cells and inhibits tumor growth in animal models of breast, colon, lung and prostate. In animal models of breast cancer, tumor growth was inhibited by up to 100 percent. In particular, the potent effect was observed in breast cancer models that represent a patient population that cannot be treated by Herceptin, the only therapeutic antibody currently approved for breast cancer treatment.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Last viewed contents

Ig Nobel Prize awarded to Takanori Takebe for "butt-breathing" study - Go ahead, crack a joke. Butt seriously, this research might save lives someday by helping people when they cannot get enough oxygen via their lungs

Ig Nobel Prize awarded to Takanori Takebe for "butt-breathing" study - Go ahead, crack a joke. Butt seriously, this research might save lives someday by helping people when they cannot get enough oxygen via their lungs

Peregrine Enters Contract Negotiations With U.S. DTRA for Hemorrhagic Fevers - U.S. Department of Defense Agency Has Selected Peregrine for a Multi-Year Award That Could Total $44.5 Million Pending Successful Contract Negotiations

Food safety in Europe - who is responsible for what? - BfR publishes 2. completely revised edition of the EU Food Safety Almanac

SemBioSys signs contract manufacturing agreement for plant-produced insulin with Cangene

Cellzome Achieves Clinical Candidate Milestone from Inflammation Alliance with GlaxoSmithKline

Bionomics BNC105 cancer clinical trials reach key milestones - Clinical program to be expanded

Crucell to sell Rhein Biotech GmbH to Dynavax

Active Biotech's nomination committee proposes election of an additional new board member

ITI Life Sciences licenses technology to Cognia to develop a database product to enhance drug discovery and development

Delisting of Merck Serono shares expected on July 18, 2007 - Squeeze Out Successfully Completed

Biotec Pharmacon's SBG shows promising effect in animal model for inflammatory bowel disease

MediGene Acquires Patents on Anti-Cancer Drugs Under Development - License agreements with the University of Chicago guarantee exclusive worldwide rights to the most important groups of patents in the field of oncolytic Herpes Simplex Viruses (HSV)